Gemtuzumab Alternatives Compared
Gemtuzumab | Cytarabine | Venclexta (venetoclax) |
|
---|
Gemtuzumab | Cytarabine | Venclexta (venetoclax) |
|
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Acute Myeloid Leukemia. Gemtuzumab may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma, Acute Nonlymphocytic Leukemia, Chronic Myelogenous Leukemia, Leukemia, Mantle Cell Lymphoma, Meningeal Leukemia. Cytarabine may also be... View more |
Prescription only
Venclexta is a BCL-2 inhibitor that may be used to treat chronic lymphocytic leukemia (CLL), small cell lymphoma (SCL), or acute myeloid leukemia. It is an oral tablet that is administered once... View more |
Related suggestions Acute Myeloid Leukemia
|
|||||||||||||||
More about Gemtuzumab | More about Cytarabine | More about Venclexta (venetoclax) | ||||||||||||||||
Ratings & Reviews | ||||||||||||||||||
Gemtuzumab has an average rating of 1.5 out of 10 from a total of 2 ratings on Drugs.com. 0% of reviewers reported a positive effect, while 100% reported a negative effect. |
Be the first to share your experience with this drug. |
Venclexta has an average rating of 8.6 out of 10 from a total of 11 ratings on Drugs.com. 82% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||
Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
View all Gemtuzumab side effects |
View all Cytarabine side effects |
View all Venclexta side effects |
||||||||||||||||
Drug Class | ||||||||||||||||||
Generic Availability | ||||||||||||||||||
N/A |
Lower cost generic |
|||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Cytarabine prices |
View all Venclexta prices |
||||||||||||||||
Dosage Forms | ||||||||||||||||||
N/A |
|
|
||||||||||||||||
Brand Names | ||||||||||||||||||
Mylotarg |
N/A |
N/A |
||||||||||||||||
Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
100 hours |
3 hours |
26 hours |
||||||||||||||||
CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
Pregnancy Category | ||||||||||||||||||
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
Drug Interactions | ||||||||||||||||||
A total of 225 drugs are known to interact with Gemtuzumab:
|
A total of 286 drugs are known to interact with Cytarabine:
|
A total of 462 drugs are known to interact with Venclexta:
|
||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||||||||||
Disease Interactions | ||||||||||||||||||
First Approval Date | ||||||||||||||||||
N/A |
N/A |
April 11, 2016 |
||||||||||||||||
WADA Class View classifications | ||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||
More Information | ||||||||||||||||||
Patient Resources | ||||||||||||||||||
Professional Resources | ||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.